PICAROS - Acalabrutinib RWE on 1L CLL in Spain
← catalyst calendarNCT05999877 · readout in 954 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
192actual
Sites
47
Country
Spain
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-07-11 | actual | When the study began enrolling |
| Primary completion | 2029-03-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-03-31 | estimated | The whole study's end, after follow-up |
| First posted | 2023-08-21 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-04 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Chronic Lymphocytic Leukemia
Primary outcomes
what the primary-completion date above is the date OFProportion of patients on acalabrutinib therapy at 24 months after treatment initiation (cohort 1).
measured 24 months after treatment initiation (cohort 1).
Real-world overall response rate (rwORR) achieved until the end of the observational period for first-line fixed duration acalabrutinib therapy (cohort 2)
measured From fixed-duration acalabrutinib start to the start date of a subsequent line therapy or study end date (cohort 2), assessed up to 25 months after the inclusion of the last patient in the cohort 2.
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed